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Abstract 
In the year 1991 Van der Bruggen P et al. cloned 
and named MAGE-1 gene that encodes MZ2E 
antigen, which is expressed in melanoma tissues 
and cell lines (van der Bruggen et al., 1991).  
Since then based on sequence similarity MAGE 
family has expanded to more than 60 genes 
(Chomez et al., 2001).  
According to their chromosomal location and 
tissue-specific expression pattern, all the members 
of this family are categorized into two groups; type 
I (cancer and testis specific) and type II 
(ubiquitous) MAGE.  
MAGEA sub-family has 12 members starting from 
MAGEA1 to MAGEA12, among them MAGEA7 
is a pseudo-gene (Doyle et al., 2010).  
The current review summarizes the information 
specifically on MAGEA3's DNA/RNA, protein 
structure, function and where the gene is 
implicated. 
Identity 
Other names: CT1.3, HIP8, HYPD, MAGE3, 
MAGEA6 
HGNC (Hugo): MAGEA3 
Location: Xq28 
Note 
MAGEA3 is the third member of MAGEA CT-
antigen family. Due to its restricted expression in 
normal testicular and placental trophoblast cells and 
aberrant expression in various types of cancer cells, 
MAGEA3 has drawn paramount attention as an 
anti-cancer immunotherapy. 
DNA/RNA 
Description 
In human X chromosome; MAGEA3, is clustered 
in q28 along with other MAGEA sub-family 
members. The gene consists of three exons and is 
distributed over 3588 bp (Figure 1). 
Transcription 
MAGEA3 gets transcribed from the reverse 
(minus/negative) strand of the DNA. The transcript 
or m-RNA harbors three exons, but only the 3rd 
exon contributes to the whole ORF (Figure 1). 
Three transcript variants have been reported till 
date. 
Protein 
Description 
The MAGEA3 protein consists of 314 amino acids. 
The protein has a molecular weight of 34747 Da 
and pI 4.57. Like other MAGEA family members, 
it has a conserved MAGE homology domain 
(MHD; 116 aa - 286 aa) (Sang et al., 2011). 
Unfortunately, till date no clear functional role has 
been identified for this domain. The protein has 
also one MAGE NH2-terminal and one MAGE 
COOH-terminal region in its structure (Figure 1). 
The MAGEA3 protein is 85% and 95% identical to 
MAGEA2 and MAGEA6, respectively 
(Atanackovic et al., 2010). 
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Figure 1. Genomic organization and protein domain structure of MAGEA3. 
 
Expression 
The expression of MAGEA3 is restricted to germ 
cells of testis (primary spermatocytes and 
spermatogonia) and placental trophoblast, but no 
other somatic cellular expression have been 
reported except in wide variety of tumor cells. 
Localisation 
Cytoplasmic and nuclear expression has been 
reported (Atanackovic et al., 2010; Barker and 
Salehi, 2002; Guo et al., 2013). 
Function 
Since the MAGA3 protein is restricted to germ cell 
of testis and trophoblast of placenta which are 
immune privileged tissues, the protein is highly 
immunogenic and recognized by CTLs when 
expressed elsewhere.  
Its role in spermatogenesis and embryo 
development is still unknown.  
A report says MAGEA3 has the ability to repress 
p53 function/transactivation, and MAGEA3 
knockdown results in increased accumulation of 
p53 target genes in response to DNA damage 
(Monte et al., 2006).  
Moreover, MAGEA3 directly interacts with and 
enhances the ubiquitin ligase activity of TRIM28 (a 
RING E3 ubiquitin ligase) and has a probable role 
in p53 degradation (Doyle et al., 2010). Its other 
functional implications in various cancer cells are 
mentioned in this report. MAGEA family members 
have significant protein sequence identity, which 
suggests a functional similarity among them. 
However, a distinct variability in the regulatory 
regions of MAGEA genes suggests a possible 
molecular mechanism of carrying out the same 
function by different members, under different 
transcription control. 
Regulation 
Till now demethylation of promoter region has 
been reported as the major regulatory mechanism 
that leads to unusual derepression of MAGEA3 in 
cancer cells (Figure 2). Histone acetylation is also 
reported to regulate the expression of MAGEA3 in 
cancer cells (Kim et al., 2006b; Wischnewski et al., 
2006). 
 
Figure 2. Role of MAGEA3-promoter methylation in spatiotemporal regulation of MAGEA3 gene expression. 
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The MAGEA3 promoter is found to be 
hypermethylated in response to FGFR2-IIIb and/or 
FGF7 stimulating signals resulting into MAGEA3 
silencing in MAGEA3-positive thyroid cancer cell 
lines (Kondo et al., 2007).  
MBD1, a methyl-CpG Binding Domain protein is 
reported to have the ability to bind the 
unmethylated promoter of MAGEA3 and 
suppresses the promoter activity that cannot be 
retracted by Ets-1 transcription factor 
(Wischnewski et al., 2007). 
Homology 
Around eight different organisms have orthologs 
with human MAGEA3. 
Implicated in 
Various cancers 
Note 
MAGEA3 expression is being reported in colorectal 
cancer, breast cancer (10%), bladder cancer (37%), 
pancreatic cancer (40%), multiple myeloma (41%), 
gastric cancer (48%), glioma (51.3%), melanoma 
(65%), thyroid cancer (65%) and NSCLC (85%). 
Information about MAGEA3 expression and 
significance in various malignancies is mentioned 
below. 
Pancreatic ductal adenocarcinoma 
Note 
MAGEA3 expression has been reported in 
pancreatic cancer cell lines and tissues.  
Its expression significantly correlates with poor 
prognosis in pancreatic cancer patients (Cogdill et 
al., 2012; Kim et al., 2006a; Kubuschok et al., 
2004). 
Colorectal cancer 
Note 
Colorectal cancer cell lines express MAGEA3 and 
its expression in tumor tissue samples significantly 
correlates with tumor size (Kim et al., 2006b; 
Shantha Kumara et al., 2012). 
Multiple myeloma 
Note 
MAGEA3 expression has been detected in multiple 
myeloma cell lines and patients samples.  
Its expression correlates with disease progression 
i.e. the frequency of expression is higher in relapsed 
patients than newly diagnosed individuals.  
Further, silencing of MAGEA3 induced intrinsic 
apoptosis pathway in proliferating multiple 
myeloma cells, which indicates the functional role 
of MAGEA3 in inhibiting apoptosis of cancer cells 
(Atanackovic et al., 2010; Nardiello et al., 2011). 
 
Thyroid carcinoma 
Note 
MAGEA3 expression has been detected in patient 
tissue samples and its expression was high in the 
small papillary carcinoma.  
Experimental evidences suggest a possible 
functional role of MAGEA3 in thyroid carcinoma 
cells' growth, invasion and metastasis (Liu et al., 
2008). 
Breast cancer 
Note 
MAGEA3 mRNA expression has been reported in 
breast cancer patient tissue samples.  
Detection of MAGEA3 mRNA in the sentinel 
lymph nodes (SLN) of breast cancer patients 
indicates a high chance of micro-metastasis.  
It is mostly expressed in the intermediate or poorly 
differentiated primary breast carcinoma, which is 
associated with poor prognosis and contributes to 
higher recurrence rate (Otte et al., 2001; Wascher et 
al., 2001). 
Lung cancer (NSCLC) 
Note 
MAGEA3 mRNA expression has been reported in 
lung cancer patient tissue samples.  
High level of MAGEA3 is a potential marker for 
poor prognosis in NSCLC patients (Gure et al., 
2005). 
Non-Hodgkins lymphoma 
Note 
MAGEA3 expression has been detected both in cell 
lines and tissue samples (at RNA level). MAGEA3 
in peripheral blood of patients can be a potential 
tumor marker and is a therapeutic target (Han et al., 
2010). 
Leukemia 
Note 
High level of MAGEA3 expression significantly 
correlates with higher bone marrow blast (Martínez 
et al., 2007). 
Glioma 
Note 
MAGE3 protein has been detected in glioma tissue 
samples. Its expression level does not reflect 
significant difference in overall survival of patients 
between the pathological grades (Guo et al., 2013). 
Gastric cancer 
Note 
Gastric cancer cell lines express MAGEA3; 
however, no functional data has been reported till 
date (Honda et al., 2004). 
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